Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$193.77 - $244.14 $307,706 - $387,694
-1,588 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $355,584 - $456,978
1,588 New
1,588 $381,000
Q2 2021

Aug 16, 2021

SELL
$259.0 - $414.71 $44.2 Million - $70.8 Million
-170,620 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$242.95 - $284.63 $36 Million - $42.1 Million
148,024 Added 655.09%
170,620 $47.7 Million
Q4 2020

Feb 16, 2021

SELL
$236.26 - $355.63 $33,312 - $50,143
-141 Reduced 0.62%
22,596 $5.53 Million
Q3 2020

Nov 16, 2020

BUY
$264.77 - $305.71 $5.44 Million - $6.29 Million
20,562 Added 945.38%
22,737 $6.45 Million
Q2 2020

Aug 17, 2020

SELL
$258.66 - $342.55 $76.9 Million - $102 Million
-297,145 Reduced 99.27%
2,175 $582,000
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $15.9 Million - $20.1 Million
-58,993 Reduced 16.46%
299,320 $94.7 Million
Q4 2019

Feb 14, 2020

BUY
$220.06 - $304.07 $10.9 Million - $15 Million
49,474 Added 16.02%
358,313 $106 Million
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $28.9 Million - $32.4 Million
133,022 Added 75.66%
308,839 $71.9 Million
Q2 2019

Aug 13, 2019

BUY
$219.29 - $241.72 $38.6 Million - $42.5 Million
175,817 New
175,817 $41.1 Million
Q3 2018

Nov 14, 2018

SELL
$293.51 - $383.83 $508,359 - $664,793
-1,732 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$257.52 - $306.91 $8.08 Million - $9.63 Million
-31,392 Reduced 94.77%
1,732 $503,000
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $6.07 Million - $8.59 Million
23,350 Added 238.9%
33,124 $9.07 Million
Q4 2017

Feb 13, 2018

SELL
$307.64 - $344.58 $1.45 Million - $1.63 Million
-4,722 Reduced 32.57%
9,774 $3.11 Million
Q3 2017

Nov 14, 2017

SELL
$281.15 - $329.69 $4.1 Million - $4.81 Million
-14,583 Reduced 50.15%
14,496 $4.54 Million
Q2 2017

Nov 09, 2017

BUY
N/A
29,079
29,079 $7.89 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.